Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac. by Matsuo, Yukinori et al.
Title
Evaluation of dynamic tumour tracking radiotherapy with real-
time monitoring for lung tumours using a gimbal mounted
linac.
Author(s)
Matsuo, Yukinori; Ueki, Nami; Takayama, Kenji; Nakamura,
Mitsuhiro; Miyabe, Yuki; Ishihara, Yoshitomo; Mukumoto,
Nobutaka; Yano, Shinsuke; Tanabe, Hiroaki; Kaneko, Shuji;
Mizowaki, Takashi; Monzen, Hajime; Sawada, Akira; Kokubo,
Masaki; Hiraoka, Masahiro
Citation
Radiotherapy and oncology : journal of the European Society














Yukinori Matsuo, MD, PhD1; Nami Ueki, MD, PhD1; Kenji Takayama, MD2; Mitsuhiro Nakamura, 6
PhD1; Yuki Miyabe, MS1; Yoshitomo Ishihara, MS1; Nobutaka Mukumoto, PhD1; Shinsuke Yano, RTT3;7
Hiroaki Tanabe, MS2; Shuji Kaneko, BS1, 4; Takashi Mizowaki, MD, PhD1; Hajime Monzen, PhD1;8
Akira Sawada, PhD5; Masaki Kokubo, MD, PhD6; and Masahiro Hiraoka, MD, PhD1.9
10
Affiliations:11
1. Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School 12
of Medicine, Kyoto, Japan13
2. Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan14
3. Clinical Radiology Service Division, Kyoto University Hospital, Kyoto, Japan15
4. Mitsubishi Heavy Industries, Ltd., Tokyo, Japan16
5. Faculty of Medical Science, Kyoto College of Medical Science, Nantan, Japan17
2 / 21
6. Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan18
19
Corresponding author:20
Yukinori Matsuo, MD, PhD.21
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto 22
University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.23
Phone: +81-75-751-3762, fax: +81-75-771-974924
E-mail: ymatsuo@kuhp.kyoto-u.ac.jp25
26
This paper consists of 21 pages and 2 tables. There are 2 supplementary figures.27
28
Running head:29
Dynamic tracking with real-time monitoring30
31





Purpose: To evaluate feasibility and acute toxicities after dynamic tumour tracking (DTT) irradiation 36
with real-time monitoring for lung tumours using a gimbal mounted linac.37
Materials and Methods: Spherical gold markers were placed around the tumour using a bronchoscope38
prior to treatment planning. Prescription dose at the isocentre was 56 Gy in 4 fractions for T2a lung 39
cancer and metastatic tumour, and 48 Gy in 4 fractions for the others. Dose-volume metrics were 40
compared between DTT and conventional static irradiation using in-house developed software.41
Results: Of twenty patients enrolled, DTT radiotherapy was successfully performed for 16 patients, 42
except 4 patients who coughed out the gold markers, one who showed spontaneous tumour regression, 43
and one where the abdominal wall motion did not correlate with the tumour motion. Dose 44
covering 95% volume of GTV was not different between the two techniques, while normal lung volume 45
receiving 20 Gy or more was reduced by 20%. A mean treatment time per fraction was 36 minutes using 46
DTT. With a median follow-up period of 13.2 months, no severe toxicity grade 3 or worse was observed.47
Conclusions: DTT radiotherapy using a gimbal mounted linac was clinically feasible for lung treatment48





Lung cancer is the leading cause of cancer-related deaths in most countries, including the US[1] and 53
Japan[2]. There have been two trends in lung cancer in recent years. The first is the shift in the patient 54
population to older ages[1,2], and the second is the gradual increase in the ratio of early stage lung 55
cancer[3,4]. Thus, development of a new treatment modality that is appropriate for elderly patients with 56
early stage lung cancer is desirable.57
Stereotactic body radiotherapy (SBRT) was developed as a new treatment modality for early stage lung 58
cancer in the late 1990s. Many retrospective studies and several multi-institutional prospective trials 59
have demonstrated that excellent local control is obtained by SBRT, with acceptable toxicity[5–7]. Thus, 60
SBRT is now an important treatment option for patients with early stage non-small-cell lung cancer who 61
are medically inoperable and those who are elderly and relatively unfit for surgery.62
The next innovation expected for lung SBRT is four-dimensional (4D) radiotherapy, which can cope 63
with tumour movement. The lung expands periodically according to respiration and a lung tumour64
moves mainly in the craniocaudal direction. The amplitude of craniocaudal tumour motion is around 1 65
cm in mean, but can be 3-4 cm in some patients[8]. When the whole trajectory of a moving tumour is 66
included in the irradiation field, larger volumes of healthy tissues are irradiated. The latter leads to a risk 67
of toxicity[9–11], and accordingly, that might limit the indication of SBRT to smaller tumours. A new 4D 68
5 / 21
irradiation technique that permits delivery of a dose to the tumour and limiting that to normal tissues by 69
coping with respiratory motion,may have the potential to improve the outcomes and to expand the 70
indications of SBRT.71
The Vero4DRT (formerly called the MHI-TM2000; Mitsubishi Heavy Industries Ltd., Tokyo, Japan, and 72
BrainLab AG, Feldkirchen, Germany)[12] has two special features that allow dynamic tumour tracking 73
(DTT) with real-time monitoring. One is two sets of kilovoltage (kV) x-ray imagers, that can monitor the 74
three-dimensional position of the tumour in real-time via implanted fiducial markers, and the other is a 75
gimbal mounted linac, enabling DTT. Extensive evaluation of the characteristics of this DTT system 76
demonstrated high accuracies in treatment delivery to a moving target[13–17]. Previous experimental 77
validation offered the required confidence for clinical implementation of DTT treatment of lung tumours. 78
The purpose of this study was to evaluate feasibility and acute toxicities after DTT radiotherapy with 79




Eligibility criteria were as follows: (1) a single lung tumour with a diameter of 50 mm or less, (2) no 84
nodal or distant metastasis, (3) respiratory tumour movement of 5 mm or more, (4) age of 20 years or 85
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above, (5) performance status of 0-2, (6) arms could be held over the head for 30 min or more, (7) doses 86
to adjacent organs not exceeding the pre-determined constraints, which were the same as in the Japan 87
Clinical Oncology Group protocol 0403[18], and (8) written informed consent. This study was approved 88




Prior to treatment planning, spherical gold markers with a diameter of 1.5 mm (FMR-201CR; Olympus 93
Medical Systems, Tokyo, Japan) were placed around the tumour under bronchoscopic guidance as an 94
internal surrogate for the tumour position. Treatment planning was carried out 1 week after insertion of 95
the gold markers. At least 3 markers were required for the DTT irradiation to be performed.96
On the simulation day, the patient was fixed in a supine position with both arms raised using an 97
individualized vacuum pillow (BodyFIX; Elekta AB, Stockholm, Sweden, or ESFORM; Engineering 98
System, Matsumoto, Japan). Ten respiratory phases of 4D CT were acquired in axial cine mode using a 99
16-slice CT scanner (LightSpeed RT16 or BrightSpeed Elite; GE Healthcare, Little Chalfont, UK) and a 100
real-time positioning management system (Varian Medical Systems, Palo Alto, US). Immediately after 101
the 4D CT scan, a breath-hold CT scan was also acquired at the end of exhalation. The breath-hold CT 102
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was sent to iPlan RT image (ver. 4.1; BrainLab AG) as a reference image. The coordinate for each phase 103
image from the 4D CT was modified so that its centroid of the fiducial markers was matched with that in 104
the breath-hold CT. Then, the 10 phase images were fused onto the breath-hold CT. After the CT scan, 105
the patient was moved to the Vero4DRT to perform a 4D modelling[14], which correlates the external 106
abdominal motion and the internal fiducial motion. The purpose of the modelling was to estimate the 4D 107
modelling error and the peak-to-peak amplitude of tumour motion.108
109
Treatment planning110
Gross tumour volumes (GTVs) were delineated on the breath-hold CT and 10 phase images. An internal 111
target volume for tracking (ITV) was defined as a composite of the eleven GTVs from the breath-hold 112
CT and the 10 phase images (Supplementary Fig. 1). Because the phase images were registered based on 113
the marker centroid, the ITV was supposed to compensate for tumour deformation and uncertainty in the 114
positional relationship between the tumour and fiducial makers during respiration[19]. Planning target 115
volume (PTV) for tracking was defined as the ITV plus setup error and additional margins to 116
compensate the 4D modeling error, baseline drift of the abdominal position, and mechanical errors of the 117
system. The setup error was estimated to be 2.5 mm in each direction as an inter-fraction positional 118
variation between the fiducials and the tumour[19]. A margin for the 4D modelling error was defined as 119
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a mean plus 2 times of standard deviation in the 4D model on the simulation day. A margin for the 120
baseline drift was estimated as 10% of the tumour motion amplitude. The mechanical errors were 121
defined as 0.5 mm[12]. The PTV margin was defined as a linear sum of these errors. At least 5 mm was 122
required for the margin.123
Monitor units (MUs) for the treatment beams were calculated using the X-ray voxel Monte Carlo 124
algorithm in iPlan RT dose (ver. 4.5.1; BrainLab AG) on the breath-hold exhale CT. The prescription 125
dose was 48 Gy in four fractions for stage IA lung cancer, and 56 Gy in four fractions for stage IB lung 126
cancer and metastatic lung tumour. This dose was prescribed at the isocentre. We typically arranged 127
seven beams: four non-coplanar and three coplanar beams. 6-MV x-ray beams were collimated to the 128
PTV plus 5-mm margin with a multi-leaf collimator. A static SBRT plan with non-tracking beams, based 129
on the motion-encompassing method[8], was also prepared as a backup if DTT irradiation could not be 130
achieved for some reason. Dose distributions were evaluated with an in-house developed software that 131
allows 4D dose calculation considering with the gimbal mounted linac[20]. The calculated dose132
distributions for the 10 phase CT images were accumulated into the exhale breath-hold CT with 133
deformable image registration using MIM Maestro (ver. 5.2; MIM Software Inc., Cleveland, OH). If the 134
dose-volume metrics in the tracking plan were diagnosed to be superior to those in the static plan, the 135
patient underwent DTT irradiation.136
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137
Irradiation of treatment beams138
First, the patient was laid on the pre-formed vacuum pillow. Set-up error was corrected for bony 139
structures using the ExacTrac X-ray system. Second, a 4D model was built to correlate the infra-red140
markers on the abdomen with the internal fiducial markers. Then, irradiation could start in dynamic 141
tracking mode with the beam following a location predicted by the 4D model based on the infra-red 142
markers placed on the patient’s abdominal wall. During irradiation, the tumour and the internal fiducials 143
were monitored visually every second with EPID and the kV imagers. If the fiducial markers displaced 144
from the predicted positions by 3 mm or more in 3 consecutive frames on the kV images, the irradiation 145
was interrupted and rebuilding the 4D model was considered.146
147
Follow-up after treatment148
Follow-up visits were planned at 2, 4, 6, 9, and 12 months within the initial year after SBRT and every 3 149
months thereafter. A CT scan was performed at each visit. The follow-up period was defined as the 150
duration between the first day of treatment and the last follow-up visit or the date of death. Acute 151
toxicity was defined as any treatment-related toxicities during the initial 6 months after the treatment. 152




Twenty-two patients were enrolled into this study between August 2011 and July 2013. No patients 156
experienced toxicities related to the insertion of fiducial markers. Twenty-two of the 101 inserted 157
markers were coughed out before the CT simulation. Consequently, the number of remaining makers in 158
4 patients decreased to two, which is insufficient for DTT to be performed. The planning procedures for 159
DTT could not be performed in another two patients. One patient showed thoracic breathing that 160
prevented the Vero system from tracking a tumour based on the abdominal motion (Supplementary Fig.161
2). In the other patient with histology-unproven primary lung cancer, the tumour spontaneously 162
regressed during 10 days between the fiducial insertion and the simulation. For the remaining 16 patients, 163
the CT simulation for DTT was successfully performed. Characteristics of the 16 patients are shown in 164
Table 1.165
The mean PTV volume reduced from 56.2 cm3 to 39.6 cm3 for the static and tracking plans, respectively166
(Table 2). GTV doses were not spoiled by the tracking method (dose covering 95% volume of GTV, 167
93.4% vs. 93.7% of the prescription dose; p = 0.323 by paired t-test). Doses to the normal lung and liver 168
were reduced in the 16 patients. Lung V20, the relative volume receiving 20 Gy or more, was reduced by 169
19.5%, from 5.5% to 4.4%. The tracking plan showed a higher maximal dose to the spinal cord than the 170
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static plan in 5 patients. However, the difference did not exceed 0.3 Gy and was considered to be 171
clinically acceptable.172
The DTT irradiation was completed for all 64 fractions for the 16 patients. Mean and standard deviation 173
in treatment time per fraction were 36.2 and 8.8 minutes (range, 19-70 minutes), respectively. The 174
treatment time exceeded 50 minutes in 5 fractions because of communication failures between the 175
tracking system and the gimbal system requiring a restart of the tracking procedure. The gold markers 176
were well recognized with kV x-ray imagers throughout all treatment fractions. The 4D modelling was 177
performed a mean of 1.9 times per fraction (range, 1 to 4).178
With a median follow-up period of 13.2 months (range, 3.4–26.5 months), one patient experienced grade 179
2 radiation pneumonitis. No severe toxicity grade 3 or worse has been observed in any of the patients.180
Two patients died of cancer, and one died of infectious pneumonia. Local tumour control was achieved 181
except one patient who developed local recurrence at 12.0 months.182
183
Discussion184
The Vero4DRT system has two major advantages. The first is that tumour position can be monitored in 185
real time using kV imagers and an EPID. The second is that no extra treatment time over static SBRT 186
and no special training for breath control are needed for the 4D treatment, which is clinically beneficial 187
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both for patient comfort and the throughput of the treatment system.188
Several uncertainties are associated with 4D irradiation, including tumour position prediction errors and 189
mechanical errors in beam delivery, which are problems to be overcome. In the Vero4DRT, kV imagers 190
can ensure that the positions of the tumour and fiducial markers correspond to the predicted sites. EPID 191
can be used to verify the tumour position in complement to the kV imagers[21]. Furthermore, log files 192
allow retrospective confirmation of the accuracy in the delivery of tumour tracking after treatment. Our 193
previous study, which evaluated the initial 10 patients from the present study cohort, confirmed high 194
accuracies in the tracking performance. The 95th percentiles of overall tracking errors were 1.3 mm, 2.4 195
mm and 1.4 mm in left-right, cranio-caudal and anterior-posterior directions, respectively[22].196
The Task Group 76 of the American Association of Physicists in Medicine classified motion 197
management methods into five types: motion-encompassing, respiratory gating, breath-hold, forced 198
shallow breathing with abdominal compression, and real-time tumour-tracking methods[8]. The 199
motion-encompassing method is the most conventional and well-established. However, it uses the largest 200
field of the five methods, with a large PTV. The breath-hold technique and abdominal compression are 201
not always suitable for frail and elderly patients. Respiratory gating needs a longer treatment time than 202
motion-encompassing methods. With a dynamic tracking method, patients do not need to hold or limit 203
their breath, and the tumour is always irradiated by the treatment beams without intermittence, leading to 204
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a shorter treatment time than the breath-hold methods or the gating methods, and a comparable treatment 205
time to the motion-encompassing methods. Dynamic tumour tracking is considered to be the favourable206
method among the five motion management methods from the patient compliance and comfort points of 207
view. According to a Japanese survey of SBRT in 2009[23], the most frequent response regarding the 208
time needed for a single daily fraction was 30 min, followed by 40 min. Our result of 36.2 min for a 209
single fraction was thus comparable with standard times for SBRT in Japan. In addition to patient 210
comfort, a few studies have suggested that prolongation of the treatment time for a single fraction may 211
reduce its biological effectiveness[24,25]. Unfortunately, considerable prolongation of treatment time212
over 50 minutes occurred in 5 fractions in the present study. The cause for the prolongation was 213
immaturity of the tracking system including software. To realize DTT irradiation, the tracking software 214
needed to communicate with other systems in real time and to command several operations including 215
control of the gimbal motion, process of signals from the infra-red camera and analysis of images from 216
the kV x-ray imagers. The tracking system had initial instability in the communication process where the 217
system could not simultaneously execute such different tasks. Some adaptations to the tracking system 218
have been introduced after the present study with the aim of improving stability. Volumetric modulated 219
arc therapy, which can reduce total MUs and consequently reduce treatment time, is being applied to 220
SBRT for the lung[26]. Arc irradiation application to DTT is needed for reduction of treatment time with 221
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the Vero4DRT. The Vero4DRT achieved the same level of geometric and dosimetric accuracy with 222
conformal arc DTT irradiation as that with fixed-port DTT[27]. A treatment planning system capable of 223
VMAT plan is under development for the Vero4DRT.224
The disadvantages of the current Vero4DRT system are its dependence on 4D modeling and fiducial 225
marker insertion. If no appropriate 4D model is acquired, dynamic tracking cannot be performed, as 226
occurred in one patient. One solution for this issue is to track a tumour based on real-time stereo 227
fluoroscopy without any 4D model. However, this method introduces another problem of skin doses due 228
to the continuous fluoroscopy during a treatment time. Another way to improve the 4D model is a 229
training to encourage for patients to perform periodical abdominal breathing[28].230
The Vero4DRT currently requires fiducial markers with x-ray fluoroscopy monitoring to detect the 231
tumour position and create the 4D model. Two types of fiducials are applicable to the Vero4DRT: one is 232
a spherical marker, and the other is a cylindrical marker. We used the spherical gold markers that were 233
inserted into a peripheral bronchiole under bronchoscopy. This method was reported in more detail by 234
Imura et al. from Hokkaido University[29]. All 57 patients in their report tolerated the marker 235
implantation procedure and only one experienced pneumothorax, which resolved with bed rest. The 236
toxicity rate was much lower than those of percutaneous insertion methods[30,31]. Trade-offs, however, 237
for the reduced toxicity are marker dislocation between insertion and radiotherapy, and positional 238
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uncertainty between the tumour and makers. Imura et al. reported that 25% of the inserted markers could 239
not be detected throughout the treatment period. Indeed, 22% of the markers in this study were coughed 240
out before the CT simulation, and 4 of 22 (18%) patients could not undergo the DTT due to the marker 241
dislocation. The reason why the Vero4DRT system requires 3 markers or more in the use of spherical 242
markers is to detect the marker dislocation. Regarding the positional uncertainty between the tumour and 243
markers, Ueki et al. evaluated intra- and interfractional variations[19]. Root mean squares in the 244
intrafractional variations were 0.6 mm, 0.9 mm and 1.5 mm in the right-left, anteroposterior and 245
craniocaudal directions, respectively. Moderate correlations of the intrafractional variation with tumour 246
motion amplitude and tumour-marker distance were observed with correlation coefficients of 0.549–247
0.780. However, the intrafractional error did not always distribute symmetrically around zero, but often 248
distributed in one side above or below zero. The direction and amplitude of the intrafractional variations 249
varied between patients. Base on the results, we judged that a uniform isotropic margin was inadequate 250
to cover the intrafractional variations, and that the fused CT approach as in the Method section was 251
suitable for DTT planning. The interfractional variation could be covered by a 2.5-mm margin.252
In conclusion, DTT radiotherapy with real-time monitoring using a gimbal mounted linac was clinically 253
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Figure legend:354
Supplementary figure 1. A schema for definition of an internal target volume (ITV) for 355
tracking356
a) An example of intrafractional change in alignment of gross tumour volume (GTV) and 357
fiducial markers, and intrafractional tumour deformation.358
b) Definition of ITV for tracking. The GTVs are fused based on the marker centroids. Then, 359
an ITV for tracking (the thick red line) is defined as a composite of the fused GTVs.360
c) A screenshot from a case. Several lines with various colours are shown around the 361
tumour, which indicate GTVs from phase images of 4D CT. An ITV (not shown) is defined as 362
a volume including all the GTVs. The outermost pink line indicates a planning target 363
volume for the ITV.364
365
Supplementary figure 2. A patient who showed thoracic breathing366
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The tumour position in the superior-inferior (SI) direction and the abdominal wall position 367
in the anterior-posterior (AP) direction are shown in blue and red lines, respectively. Note 368
that the patient showed thoracic breathing where the tumour moved without any 369
abdominal motion during the initial 10 seconds. Thoracic breathing was the dominant 370
respiratory pattern in the patient so that the Vero system could not create an appropriate 371
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